Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00778700 · ClinicalTrials.gov registry record · Phase 2
A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Participants With Plaque Psoriasis
A Phase 2 study of Psoriasis, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 199
- Enrollment target
- 20
- Study locations
NCT00778700 is a Phase 2 study of Psoriasis that has completed, run by Incyte Corporation. The registered enrollment target is 199 participants, below the 487-participant average among 125 other Psoriasis trials with a reported enrollment target (59% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT00778700, a Phase 2 study of Psoriasis, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 199 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study was double-blind, randomized, vehicle-controlled study with application of Ruxolitinib phosphate cream or vehicle cream in participants with stable plaque psoriasis applied once daily for 12 weeks without occlusive dressings. There were 4 treatment groups anticipated to have 50 participants in each.
Conditions Studied
Interventions
- DRUG Ruxolitinib Phosphate
- OTHER Placebo Cream
Study Locations (20)
California
- - Los Angeles
- - San Diego
- - Santa Monica
- - Vallejo
Florida
- - Miami
- - Ormond Beach
Illinois
- - Naperville
- - Wheaton
Indiana
- - Evansville
- - South Bend
Arkansas
- - Hot Springs
Connecticut
- - New Haven
Massachusetts
- - Boston
Michigan
- - Clinton Township
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 199 participants |
| Start Date | 2008-10-28 |
| Est. Completion | 2009-06-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00778700
The ClinicalTrials.gov registry entry for NCT00778700 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 199 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 487-participant average among 125 other Psoriasis trials with a reported enrollment target (59% lower). The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Ruxolitinib Phosphate is the first listed.
NCT00778700 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT00778700 about?
NCT00778700 is a clinical study titled "A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Participants With Plaque Psoriasis". The study was double-blind, randomized, vehicle-controlled study with application of Ruxolitinib phosphate cream or vehicle cream in participants with stable plaque psoriasis applied once daily for 12 weeks without occlusive dressings. There were 4 treatment groups anticipated to have 50 participant...
What is the current status of trial NCT00778700?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 199 participants. The study started on 2008-10-28. Estimated completion is 2009-06-26.
What conditions does trial NCT00778700 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT00778700?
The interventions under investigation include: Ruxolitinib Phosphate (DRUG), Placebo Cream (OTHER).
Who is sponsoring clinical trial NCT00778700?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00778700 being conducted?
This trial has 20 study locations across Arkansas, California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study in Participants With Moderate to Severe Psoriasis
COMPLETED · Phase 2
-
Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 2
-
A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate)
COMPLETED · Phase 2
-
Etanercept With Tacrolimus for Psoriasis
COMPLETED · Phase 2
-
A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 2
-
A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.